Interestingly, we found an increased percentage of MHCII+CD11c+ DC expressing CXCL9 in the tumor mass upon administration of anti–CTLA-4 antibody and Tα1 (Fig 6B and C), suggesting that Tα1 can indeed modify the chemokine profile at the tumor site likely by regulating the expression program of DCs. This evidence concerns the gene CTLA4 and neoplasm.